Yannis Hamidou | Immunotherapy |

Published on by Top Pharmaceutical

Mr. Yannis Hamidou | Immunotherapy | Best Researcher Award

Yannis Hamidou at Amiens Picardie University Hospital | France

Mr. Yannis Hamidou is a dedicated rheumatologist currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, France. With a strong academic background in medical sciences, rheumatology, and sports medicine, he has actively contributed to clinical research focusing on autoimmune and inflammatory diseases. His expertise spans therapeutic innovations, patient-centered care, and multidisciplinary collaborations aimed at improving outcomes in rheumatology and intensive care settings. Through his clinical practice and research endeavors, Mr. Hamidou has developed a reputation for excellence in precision treatment strategies and evidence-based medicine, significantly impacting rheumatology healthcare and contributing to advancements in patient management practices.

Publication Profile 

Orcid

Education 

Mr. Yannis Hamidou completed his postgraduate diploma in medical sciences, laying the foundation for his medical career. He successfully defended his medical thesis , advancing his academic and clinical expertise. To specialize further, he obtained a postgraduate diploma in rheumatology, focusing on autoimmune and inflammatory disorders. Additionally, he completed a specialization in sports medicine and earned the BPC certification, broadening his clinical competencies. This comprehensive academic training has equipped him with extensive knowledge across internal medicine, rheumatology, and sports-related healthcare, preparing him for leadership roles in clinical care, research, and education.

Experience 

Mr. Yannis Hamidou is currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, where he integrates clinical care with research responsibilities. His work in intensive care medicine includes serving as Principal Investigator for an observational clinical study, focusing on chronic inflammatory diseases in critical care settings. Alongside his clinical duties, he actively participates in developing patient-specific treatment strategies for autoimmune and rheumatologic disorders. His multidisciplinary experience spans rheumatology, sports medicine, and internal medicine, providing comprehensive care solutions. He also contributes to academic teaching and mentoring, fostering evidence-based clinical practices while engaging in ongoing research aimed at improving patient outcomes.

Awards and Honors 

Mr. Yannis Hamidou academic achievements and clinical leadership reflect his professional excellence. His appointments, including Clinic Chief Assistant at CHU Amiens-Picardie and Principal Investigator roles in clinical studies, highlight his recognition within the medical community. His selection for advanced training in rheumatology, sports medicine, and critical care research further emphasizes his commitment to advancing medical science. Future recognitions are anticipated as his contributions to rheumatology research, patient care innovations, and academic scholarship continue to grow, positioning him as a promising leader in the field of rheumatology and clinical medicine in France.

Research Focus 

Mr. Yannis Hamidou research primarily targets autoimmune and inflammatory disorders, with a focus on therapeutic innovations and patient outcome optimization. His work in rheumatology explores the long-term maintenance of advanced therapies like Janus kinase inhibitors and investigates biomarkers such as fecal calprotectin for early disease detection. Additionally, he has contributed to understanding mortality causes in intensive care settings among patients with chronic inflammatory diseases. By integrating real-world data and observational clinical research, his studies aim to refine diagnostic precision, enhance treatment strategies, and inform evidence-based clinical guidelines, ultimately improving healthcare delivery for patients with complex rheumatologic conditions.

Publication Top Notes

Rulla Tamimi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Rulla Tamimi | Immunotherapy | Best Researcher Award

Dr. Rulla Tamimi at Weill Cornell Medicine Dept of Healthcar, United States.

Dr. Rulla M. Tamimi is a leading cancer epidemiologist and Professor of Population Health Sciences and Pathology at Weill Cornell Medicine. With over two decades of experience in breast cancer research, her work centers on cancer risk prediction, environmental exposures, and molecular epidemiology. A pioneer in integrating biomarkers and epidemiologic data, she has advanced understanding of breast cancer heterogeneity and disparities. Dr. Tamimi is also a principal investigator for multiple NIH-funded studies and a dedicated educator. She plays a critical role in shaping future public health strategies and improving women’s health through rigorous research and community-engaged science.

Publication Profile 

Scopus

Education

Dr. Tamimi holds a B.S. in Biology from Tufts University (1993), followed by an M.S. (1999) and Sc.D. (2003) in Epidemiology from the Harvard T.H. Chan School of Public Health. Her academic training is rooted in public health, statistical methods, and cancer epidemiology. She received advanced training at Harvard, which set the stage for a prolific research and academic career in molecular and clinical epidemiology. Her education enabled her to translate complex biological mechanisms into population-level cancer prevention strategies, and her leadership has consistently bridged rigorous epidemiological research with patient-focused public health innovation.

Experience

Dr. Tamimi has held prestigious academic positions including Instructor, Assistant Professor, Associate Professor at Harvard Medical School and Harvard T.H. Chan School of Public Health (2003–2020). She currently serves as Professor at Weill Cornell Medicine (2020–Present). With over 20 years in academic medicine, she’s also served as Associate Epidemiologist at Brigham and Women’s Hospital. Dr. Tamimi leads NIH- and NCI-funded multi-institutional projects, mentoring future epidemiologists while advancing cancer research. She has contributed to global education through lectures and program direction across institutions including Boston University, Harvard, and National University of Singapore.

Awards 

Dr. Tamimi has received multiple accolades for her visionary research. She earned the “Good Questions Meet Big Data” Ideation Challenge Award from Harvard Catalyst in 2017 and became a Susan G. Komen Scholar in 2020. Her election to prominent organizations such as the American Association for Cancer Research, Society for Epidemiologic Research, and Cornell Center for Health Equity highlights her influence in the field. These recognitions reflect her leadership in molecular epidemiology, commitment to health equity, and significant contributions to cancer prevention research on both national and global scales.

Research Focus 

Dr. Tamimi’s research explores breast cancer heterogeneity, environmental exposures, and the biological underpinnings of cancer risk. Her projects evaluate how dietary carotenoids, genetic variants, circulating metabolites, and breast tissue markers influence cancer outcomes. She is especially interested in aggressive tumor subtypes, breast cancer in young women, and disparities across racial and socioeconomic lines. Current studies also examine stromal contributions to carcinogenesis and social determinants of health through the SoCa Center. Her work connects molecular biology with epidemiological insights to improve early detection, prevention, and personalized treatment strategies for breast cancer.

Publication Top Notes

  • Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
  • Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts
  • Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States
  • Thromboembolic Events Are Increased After Splenectomy in Postmenopausal Women
  • The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages
  • The impact of reproductive factors on breast tumor and normal-adjacent tissue immune profile from menarche to menopause
  • Associations of alcohol consumption with expression of CD44, CD24, and ALDH1A1 stem cell markers in benign breast biopsy samples
  • Breast cancer prevention by short-term inhibition of TGFβ signaling
  • Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study
  • A genome-wide association study of mammographic texture variation

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Dr. Efthalia Zervoudi, Hellenic Pasteur Institute, Greece

Dr. Efthalia Zervoudi is a senior researcher at the Hellenic Pasteur Institute with a PhD in Biochemistry from the University of Athens. Her research focuses on designing inhibitors targeting antigen-trimming aminopeptidases, contributing significantly to immunology and cancer biology. She has extensive experience in oncology and molecular biomarkers, having held positions at Cardiff University and University Hospital “Attikon.” Dr. Zervoudi has authored multiple influential publications and holds patents on aminopeptidase inhibitors. She has received prestigious fellowships, including the Welcome Trust ISSF fellowship, and continues to advance personalized medicine through innovative molecular diagnostic approaches.

Publication Profile

Google Scholar

Education

I completed my PhD in Biochemistry at the University of Athens (2012–2016) with top honors, focusing on designing inhibitors targeting antigen-trimming aminopeptidases. Before that, I earned my Master’s degree in Biochemistry from the same university (2010–2012), studying the specificity pockets of aminopeptidases involved in antigen processing. My academic journey began with a Bachelor’s degree in Chemistry from the University of Patras (2003–2008), where I researched proteoglycans in cancer patients under Prof. Dimitrios Vynios. 🎓 Prior to university, I graduated high school with a strong average score of 18.5/20, marking the start of my scientific path.

Experience

Dr. Efthalia Zervoudi is currently serving as a Senior Researcher at the Hellenic Pasteur Institute (2024–present), contributing to cutting-edge biomedical research. From 2019 to 2023, she was a Research Coordinator at the Oncology Unit of University Hospital “Attikon” in Greece. 🏥 Previously, she held a postdoctoral research position at Cardiff University’s School of Medicine (2016–2019), specializing in Infection and Immunity. 🔬 Between 2010 and 2015, she collaborated with the Protein Chemistry Lab at the National Centre for Scientific Research “DEMOKRITOS”, working on the project: “Rational design and development of inhibitors for targeting antigen-trimming aminopeptidases.”

Awards

Dr. Efthalia Zervoudi has received several prestigious fellowships and awards recognizing her impactful research. In 2020, she was awarded funding by the Hellenic Society of Oncology for her study on Endoplasmic Reticulum Associated Peptidases as tools to understand cancer. 🧪 In 2015, she received the esteemed Wellcome Trust ISSF Fellowship at Cardiff University. 🇬🇧 Earlier, in Fall 2014, the Hellenic Academy of Athens honored her with the “Axillea and Aikaterini Dionysopoulou” award for her groundbreaking work on rationally designed inhibitors enhancing antigen presentation and cytotoxic T-cell responses. 🔬🎖️ Her research continues to push scientific boundaries.

Research Focus

Dr. Efthalia Zervoudi is a leading researcher in immunology and molecular biology, with a focus on antigen processing, immune regulation, and aminopeptidase function. Her work explores how enzymes like ERAP1 and ERAP2 trim antigenic peptides for presentation by MHC class I molecules, enhancing cytotoxic T-cell responses—a crucial process in cancer immunotherapy and autoimmune disease research. 🧬 She also develops targeted inhibitors to modulate immune responses, contributing to vaccine design and tumor immunity. 🧪 Her research bridges biochemistry, structural biology, and immuno-oncology, with potential applications in personalized medicine.

Publication Top Notes

Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses

Probing the S1 specificity pocket of the aminopeptidases that generate antigenic peptides

A common single nucleotide polymorphism in endoplasmic reticulum aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

Optimized peptide–MHC multimer protocols for detection and isolation of autoimmune T-cells

A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition

Autoimmune disease-associated variants of extracellular endoplasmic reticulum aminopeptidase 1 induce altered innate immune responses by human immune cells

3, 4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties

Novel selective inhibitors of aminopeptidases that generate antigenic peptides

Dual molecular mechanisms govern escape at immunodominant HLA A2-restricted HIV epitope

A common SNP in ER aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway

Correction: Konstantopoulos et al. HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway. Viruses 2024, 16, 113

Dr. Marc Bender|Immunotherapy |Best Researcher Award

Published on by Top Pharmaceutical

Dr. Marc Bender|Pharmaceutical Chemistry |Best Researcher Award|

Dr. Marc Bender at abriz University of Medical Sciences, Iran

PROFILE  

orcid

Early Academic Pursuits 📚

Marc Bender’s academic journey began with a strong foundation in molecular biology, earning a (link unavailable) and (link unavailable) from Universität Hamburg. He furthered his expertise by pursuing a doctorate in skin cancer research at the department of dermatology, Elbe Klinikum Buxtehude. His thesis focused on elucidating molecular mechanisms, particularly epigenetic regulation via miRNAs, involved in tumor progression of cutaneous squamous cell carcinoma.

Professional Endeavors 💼

As a data scientist, Marc contributed to the European melanoma registry (EUMelaReg), evaluating retrospective data for real-world clinical trials. This experience deepened his understanding of melanoma and immunotherapy, and he developed skills in statistical methods and programming. His professional endeavors have been marked by a commitment to advancing cancer research and treatment.

Contributions and Research Focus 🔬

Marc’s research focus encompasses various aspects of skin cancer, including:

– Investigating effects of combined UVA, UVB, visible light, and infrared radiation on human skin cells (KAUVIR)
– Examining the influence of UVA and UVB irradiation on human dermal stem cells (UV-DHDS)
– Comparing treatments for melanoma, including anti-PD1 monotherapy and BRAF/MEK inhibitor treatment (PDSeq and EMRSeq)
– Analyzing immune checkpoint inhibitor maintenance treatment after achieving a partial or complete response (EUMelaReg)

Accolades and Recognition 🏆

Marc’s work has been recognized through publications in esteemed journals, including:

– Journal of Cancer Research and Clinical Oncology
– Journal of Photochemistry and Photobiology B Biology
– Cancers (MDPI)
– Journal of Clinical Oncology (conference paper)
– Annals of Oncology (conference paper)

Impact and Influence 🌟

Marc’s research has contributed significantly to the understanding of skin cancer mechanisms and treatment options. His work has:

– Advanced knowledge of miRNA expression and its association with tumor progression
– Investigated treatment adherence in patients with stage III melanoma
– Compared outcomes of different treatment approaches for metastatic melanoma

Legacy and Future Contributions 🌱

As a dedicated researcher, Marc continues to contribute to the field of skin cancer research. His future endeavors will likely focus on:

– Furthering understanding of molecular mechanisms in skin cancer
– Developing innovative treatment approaches
– Collaborating with international researchers to advance cancer research

Marc’s legacy will be marked by his commitment to advancing cancer research, improving treatment options, and enhancing patient outcomes. His work will continue to influence the scientific community, inspiring future generations of researchers.

🎓Publication 

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

  • Authors   : Marc Bender
  • Journal    :Cancers
  • Year         :2022

UVB damage response of dermal stem cells as melanocyte precursors compared to keratinocytes, melanocytes, and fibroblasts from human foreskin

  • Authors   :Marc Bender
  • Journal    :Photochemistry and Photobiology B: Biology
  • Year         :2021

UV-type specific alteration of miRNA expression and its association with tumor progression and metastasis in SCC cell lines

  • Authors   : Marc Bender
  • Journal    :Cancer Research and Clinical Oncologyy
  • Year         :2020

 

Assist Prof Dr. Hossam Hwihy|Immunotherapy |Best Researcher Award

Published on by Top Pharmaceutical

Assist Prof Dr. Hossam Hwihy, Immunotherapy ,Excellence in Innovation Awards

Assist Prof Dr. Hossam Hwihy at Faculty of science Al-Azhar University,Egypt

PROFILE  

scopus

 

Early Academic Pursuits 🎓

Dr. Hossam Mohammed Sayed Hwihy, an Egyptian national born on September 9, 1985, embarked on his academic journey with a deep passion for marine biology and environmental sciences. He completed his B.Sc. in Science with a specialization in Marine Biology from Al-Azhar University, Cairo, in 2007. His early academic pursuits were driven by a keen interest in understanding the complex interactions within marine ecosystems and the impact of human activities on these delicate environments. This foundational knowledge paved the way for his subsequent research in marine pollution and aquaculture, fields in which he would later make significant contributions.

To further his expertise, Dr. Hwihy pursued a Master’s degree in Marine Pollution at Al-Azhar University, graduating in 2018. His research during this period focused on the detrimental effects of pollutants on marine life, particularly how they affect aquatic organisms at the cellular and biochemical levels. His academic journey continued with a Ph.D. in Marine Biology from the same institution, which he completed in 2021. His doctoral research was instrumental in deepening his understanding of marine ecosystems and their responses to environmental stressors.

Professional Endeavors 💼

Dr. Hwihy’s professional career is marked by his dedication to both teaching and research in the field of marine biology and aquaculture. Starting as a Teaching Assistant in Zoology at Al-Azhar University in 2016, he quickly established himself as an enthusiastic and knowledgeable educator. He was involved in teaching a range of courses including Aquaculture, Fish Biology, Marine Pollution, and Seafood Processing to undergraduate students. His teaching philosophy emphasizes the practical application of theoretical knowledge, which has been well-received by his students.

In December 2021, Dr. Hwihy was appointed as a Lecturer and Postdoctoral Researcher at the Faculty of Science and Education, Al-Azhar University, Cairo. In this role, he has continued to contribute to the academic community through his teaching and research. Additionally, he is a founding member of the Al-Azhar Aquaponic Experimental Farm, a pioneering project that integrates aquaculture with hydroponics to create a sustainable food production system. This initiative highlights his commitment to advancing sustainable practices in aquaculture.

Contributions and Research Focus 🔬

Dr. Hwihy’s research contributions span several critical areas within marine biology and aquaculture. His primary research interests include:

  1. Aquaponics Management Systems: Dr. Hwihy has been at the forefront of research into aquaponics, a sustainable farming technique that combines aquaculture (raising fish) with hydroponics (growing plants without soil). His work focuses on optimizing these systems to enhance yield production while minimizing environmental impact.
  2. Nanotechnology in Aquatic Applications: He is actively involved in studying the effects of various nanomaterials on aquatic ecosystems, particularly how these materials can be used to address environmental challenges in aquaculture, such as pollution and disease management.
  3. Climate Change and Molecular Responses: Dr. Hwihy’s research also delves into the impacts of climate change on marine life, particularly at the molecular level. He is investigating how changes in temperature and other environmental factors influence the genetic and physiological responses of marine organisms.
  4. Marine Bioactive Materials and Toxins: His work in this area focuses on the application of marine-derived compounds in managing fish diseases and addressing environmental issues in aquaculture. This research is critical for developing new strategies to enhance the sustainability of fish farming.
  5. Artificial Intelligence in Aquaculture: Dr. Hwihy is exploring the use of artificial intelligence (AI) to improve the management of aquaculture systems. His research aims to develop AI-based tools for monitoring water quality, predicting fish health, and optimizing feeding strategies.

Accolades and Recognition 🏆

Throughout his career, Dr. Hwihy has been recognized for his contributions to marine biology and aquaculture. He has presented his research at numerous conferences and workshops, sharing his insights with the global scientific community. Notable among these is his presentation at the 9th International Conference for Basic Sciences (ISCAZ) in 2017, where he discussed the lethal toxicity of Profenofos and Sesbania sesban on freshwater snails. His work in this area has been published, further establishing his reputation as a researcher of note.

Dr. Hwihy has also been a caller and participant in various workshops, including those focused on aquaponics, nanotechnology, and the application of artificial intelligence in scientific research. His involvement in these events reflects his commitment to continuous learning and knowledge dissemination.

Impact and Influence 🌍

Dr. Hwihy’s work has had a significant impact on the field of aquaculture and marine biology, particularly in Egypt. His research on aquaponics and sustainable aquaculture practices has the potential to revolutionize food production in regions facing water scarcity and environmental degradation. By integrating innovative technologies such as nanotechnology and AI into aquaculture, he is helping to pave the way for more resilient and efficient farming systems.

His contributions extend beyond academia, as he actively engages in community outreach through workshops and seminars aimed at educating the public and industry stakeholders about the benefits of sustainable aquaculture. His role as a founding member of the Al-Azhar Aquaponic Experimental Farm is particularly noteworthy, as it serves as a model for future aquaculture projects in Egypt and beyond.

Legacy and Future Contributions 🚀

As a leading figure in the field of aquaculture and marine biology, Dr. Hwihy’s legacy is one of innovation and sustainability. His research has laid the groundwork for future advancements in sustainable food production, particularly in arid regions where traditional farming methods are less viable. His work in nanotechnology and AI is likely to have far-reaching implications for the future of aquaculture, making it more efficient and environmentally friendly.

🎓Publication 

Threat of heavy metal pollutants and parasites to freshwater fish with special reference to their risk of cancer to humans in Egypt

  • Authors   :Afifi, M.A.M., Radwan, M., Abbas, M.M.M., … Alabssawy, A.N., Khalaf-Allah, H.M.M.
  • Journal    :Aquaculture
  • Year         :2024

Biofloc biosecurity: A revolutionary paradigm in augmenting aquaculture health and resilience against Aeromonas hydrophila

    • Authors :Hwihy, H.M., Zeina, A.F., Abu Husein, M.S., El-Tabakh, M.A.M.
    • Journal   :Aquaculture and Fisheries
    • Year       : 2024

Evaluating of Pea Peels Meal as a Fishmeal alternative in Formulated Diet Ingredients of Oreochromis niloticus

UPLC/ESI/MS profiling of red algae Galaxaura rugosa extracts and its activity against malaria mosquito vector, Anopheles pharoensis, with reference to Danio rerio and Daphnia magna as bioindicators

  • Authors  :El-Tabakh, M.A.M., Elhawary, E.A., Hwihy, H.M., … Bakr, N.A., Shehata, A.Z.I.
  • Journal   :Malaria Journal
  • Year        :   2023

DNA Barcoding and Sensitivity of Dengue Vector Aedes aegypti (Linnaeus, 1762) (Diptera: Culicidae) Aquatic Stages to Different Insecticides with Reference to Non-Target Organisms, Danio rerio and Daphnia magna